RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-1.17%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$2.99B
AUM Growth
+$2.99B
(-15%)
Cap. Flow
-$78.8M
Cap. Flow
% of AUM
-2.64%
Top 10 Holdings %
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
15
Top Buys
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$114M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$86.8M |
| 3 |
ALLK
Allakos
ALLK
|
$61.1M |
| 4 |
IGMS
IGM Biosciences
IGMS
|
$55.8M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
$55.1M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$405M |
| 2 |
eHealth
EHTH
|
$76.5M |
| 3 |
Sarepta Therapeutics
SRPT
|
$62.6M |
| 4 |
Elevance Health
ELV
|
$51.8M |
| 5 |
Teladoc Health
TDOC
|
$30.7M |
Sector Composition
| 1 | Healthcare | 97.74% |
| 2 | Energy | 0.01% |
| 3 | Technology | 0% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
26
DELISTED
Immunogen Inc
IMGN
| $35.4M | 1.18% |
14,616,560
+661,766
| +5% | +$1.6M |
|
27
Centene
CNC
$14.8B
| $35.1M | 1.17% |
810,498
+119,628
| +17% | +$5.18M |
|
|
EIDX
28
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $33.2M | 1.11% |
923,003
+44,600
| +5% | +$1.6M |
|
29
Replimune Group
REPL
$460M
| $30.8M | 1.03% |
2,213,417
+16,414
| +0.7% | +$228K |
|
30
Xencor
XNCR
$594M
| $29.7M | 0.99% |
879,627
-733,171
| -45% | -$24.7M |
|
31
Xeris Biopharma Holdings
XERS
$1.27B
| $29.5M | 0.99% |
3,000,641
| – | – |
|
32
HCA Healthcare
HCA
$95.4B
| $28.4M | 0.95% |
+235,500
| New | +$28.4M |
|
|
TCRR
33
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $26.9M | 0.9% |
1,790,288
-8,928
| -0.5% | -$134K |
|
|
GRTS
34
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $26.8M | 0.9% |
3,104,494
-111,500
| -3% | -$963K |
|
35
Akero Therapeutics
AKRO
$3.65B
| $26.5M | 0.89% |
1,164,402
-4,400
| -0.4% | -$100K |
|
36
Scholar Rock
SRRK
$3.3B
| $25.6M | 0.86% |
2,857,389
-63,000
| -2% | -$564K |
|
37
LivaNova
LIVN
$3.09B
| $25.3M | 0.85% |
342,987
-81,000
| -19% | -$5.98M |
|
38
Genmab
GMAB
$16.7B
| $25.3M | 0.85% |
+1,248,600
| New | +$25.3M |
|
39
Jazz Pharmaceuticals
JAZZ
$7.99B
| $24M | 0.8% |
187,599
+19,212
| +11% | +$2.46M |
|
|
PRNB
40
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $22.3M | 0.75% |
790,006
+545,906
| +224% | +$15.4M |
|
41
Stoke Therapeutics
STOK
$1.08B
| $21.9M | 0.73% |
1,017,478
-4,330
| -0.4% | -$93.1K |
|
|
AXNX
42
DELISTED
Axonics, Inc. Common Stock
AXNX
| $21.8M | 0.73% |
809,700
-3,800
| -0.5% | -$102K |
|
43
AnaptysBio
ANAB
$630M
| $21.4M | 0.72% |
612,558
+2,900
| +0.5% | +$101K |
|
|
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $20.1M | 0.67% |
773,571
+32,900
| +4% | +$856K |
|
|
CBAY
45
DELISTED
Cymabay Therapeutics
CBAY
| $16M | 0.53% |
3,115,865
-22,500
| -0.7% | -$115K |
|
|
HOOK
46
DELISTED
HOOKIPA Pharma
HOOK
| $14.2M | 0.48% |
1,897,721
+5,842
| +0.3% | +$43.8K |
|
|
CLVS
47
DELISTED
Clovis Oncology, Inc.
CLVS
| $14.2M | 0.47% |
3,607,800
+145,500
| +4% | +$572K |
|
|
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $13.9M | 0.47% |
1,139,106
-1,200
| -0.1% | -$14.7K |
|
49
Adaptive Biotechnologies
ADPT
$1.96B
| $13.1M | 0.44% |
424,000
-1,000
| -0.2% | -$30.9K |
|
50
Stereotaxis
STXS
$246M
| $11.5M | 0.39% |
+3,285,000
| New | +$11.5M |
|